Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Portfolio Pulse from
Geron Corporation announced that the CHMP of the EMA has given a positive opinion recommending the approval of RYTELO (imetelstat) for treating adults with transfusion-dependent anemia due to lower-risk MDS.
December 13, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron Corporation's RYTELO (imetelstat) received a positive opinion from the CHMP, recommending its approval for treating transfusion-dependent anemia in Europe.
The positive CHMP opinion is a significant regulatory milestone for Geron, potentially leading to market approval in Europe. This can enhance Geron's market presence and revenue potential, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100